cbdMD (YCBD) Total Non-Current Liabilities (2016 - 2025)
cbdMD (YCBD) reported Total Non-Current Liabilities of $201235.0 for Q2 2025, down 93.2% on a YoY basis from $3.0 million in Q2 2024, and down 49.71% sequentially from $400144.0 in Q1 2025.
cbdMD (YCBD) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends
cbdMD (YCBD) has 10 years of Total Non-Current Liabilities data on file, last reported at $201235.0 in Q2 2025.
- For the quarter ending Q2 2025, Total Non-Current Liabilities fell 93.2% year-over-year to $201235.0; the trailing twelve-month figure through Jun 2025 stood at $201235.0 (down 93.2% YoY), and the FY2023 full-year result was $2.5 million, down 38.91% from the prior year.
- Total Non-Current Liabilities eased to $201235.0 in Q2 2025, from $400144.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $28.3 million in Q1 2021 to a low of $201235.0 in Q2 2025.
- A 5-year average of $6.5 million and a median of $3.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 93.46% in 2021 and slumped 93.2% in 2025, its largest moves.
- Tracing YCBD's Total Non-Current Liabilities over 5 years: stood at $8.2 million in 2021, then slumped by 56.11% to $3.6 million in 2022, then slumped by 41.77% to $2.1 million in 2023, then slumped by 71.65% to $591583.0 in 2024, then sank by 65.98% to $201235.0 in 2025.
- Business Quant data shows YCBD's Total Non-Current Liabilities at $201235.0 in Q2 2025, $400144.0 in Q1 2025, and $591583.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 201,235.00 |
| Mar 31, 2025 | 400,144.00 |
| Dec 31, 2024 | 591,583.00 |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Sep 30, 2023 | 2.49 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 3.22 Mn |
| Dec 31, 2022 | 3.58 Mn |
| Sep 30, 2022 | 4.08 Mn |
| Jun 30, 2022 | 4.81 Mn |
| Mar 31, 2022 | 7.18 Mn |
| Dec 31, 2021 | 8.17 Mn |
| Sep 30, 2021 | 14.82 Mn |
| Jun 30, 2021 | 19.49 Mn |
| Mar 31, 2021 | 28.31 Mn |
| Dec 31, 2020 | 31.62 Mn |
| Sep 30, 2020 | 23.97 Mn |
| Jun 30, 2020 | 23.34 Mn |